Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 5
2009 6
2010 6
2011 6
2012 12
2013 14
2014 14
2015 10
2016 16
2017 14
2018 6
2019 7
2020 1
2021 6
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, Lugemwa A, Cressey TR, Musoke P, Variava E, Cotton MF, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch SB, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe GM, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Saïdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb DM; ODYSSEY Trial Team. Turkova A, et al. N Engl J Med. 2021 Dec 30;385(27):2531-2543. doi: 10.1056/NEJMoa2108793. N Engl J Med. 2021. PMID: 34965338 Free PMC article. Clinical Trial.
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Turkova A, White E, Kekitiinwa AR, Mumbiro V, Kaudha E, Liberty A, Ahimbisibwe GM, Moloantoa T, Srirompotong U, Mosia NR, Puthanakit T, Kobbe R, Fortuny C, Kataike H, Bbuye D, Na-Rajsima S, Coelho A, Lugemwa A, Bwakura-Dangarembizi MF, Klein N, Mujuru HA, Kityo C, Cotton MF, Ferrand RA, Giaquinto C, Rojo P, Violari A, Gibb DM, Ford D; ODYSSEY trial team. Turkova A, et al. Lancet Child Adolesc Health. 2023 Oct;7(10):718-727. doi: 10.1016/S2352-4642(23)00164-5. Epub 2023 Aug 8. Lancet Child Adolesc Health. 2023. PMID: 37562418 Free PMC article. Clinical Trial.
Impact of orphan status on HIV treatment outcomes and retention in care of children and adolescents in Asia.
Huy BV, Teeraananchai S, Oanh LN, Tucker J, Kurniati N, Hansudewechakul R, Truong KH, Khol V, Nguyen LV, Chau Do V, Lumbiganon P, Kongstan N, Bunupuradah T, Sudjaritruk T, Kumarasamy N, Yusoff NK, Mohd Razali KA, Wati DK, Fong MS, Nallusamy R, Kariminia A, Sohn AH. Huy BV, et al. Among authors: bunupuradah t. J Virus Erad. 2016 Oct 5;2(4):227-231. J Virus Erad. 2016. PMID: 27781105 Free PMC article.
Control lymphocyte subsets: can one country's values serve for another's?
Mandala WL, Ananworanich J, Apornpong T, Kerr SJ, MacLennan JM, Hanson C, Jaimulwong T, Gondwe EN, Rosenblatt HM, Bunupuradah T, Molyneux ME, Spector SA, Pancharoen C, Gelman RS, MacLennan CA, Shearer WT. Mandala WL, et al. Among authors: bunupuradah t. J Allergy Clin Immunol. 2014 Sep;134(3):759-761.e8. doi: 10.1016/j.jaci.2014.06.030. J Allergy Clin Immunol. 2014. PMID: 25171870 Free PMC article.
Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients.
Singkham N, Avihingsanon A, Brundage RC, Birnbaum AK, Thammajaruk N, Ruxrungtham K, Bunupuradah T, Kiertiburanakul S, Chetchotisakd P, Punyawudho B; LASA study team. Singkham N, et al. Among authors: bunupuradah t. Expert Rev Clin Pharmacol. 2022 Jan;15(1):99-108. doi: 10.1080/17512433.2022.2000858. Epub 2021 Nov 26. Expert Rev Clin Pharmacol. 2022. PMID: 34727835
119 results